Nisa Investment Advisors LLC Sells 3,894 Shares of Bristol-Myers Squibb Co (NYSE:BMY)

Nisa Investment Advisors LLC lowered its stake in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 0.6% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 595,340 shares of the biopharmaceutical company’s stock after selling 3,894 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Bristol-Myers Squibb were worth $30,190,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Lodestar Investment Counsel LLC IL raised its stake in shares of Bristol-Myers Squibb by 5.2% during the second quarter. Lodestar Investment Counsel LLC IL now owns 113,720 shares of the biopharmaceutical company’s stock worth $5,157,000 after acquiring an additional 5,579 shares in the last quarter. Cypress Capital Management LLC raised its stake in shares of Bristol-Myers Squibb by 21.2% during the second quarter. Cypress Capital Management LLC now owns 154,335 shares of the biopharmaceutical company’s stock worth $6,999,000 after acquiring an additional 26,990 shares in the last quarter. Nachman Norwood & Parrott Inc raised its stake in shares of Bristol-Myers Squibb by 3.5% during the second quarter. Nachman Norwood & Parrott Inc now owns 50,388 shares of the biopharmaceutical company’s stock worth $2,285,000 after acquiring an additional 1,687 shares in the last quarter. Edge Wealth Management LLC raised its stake in shares of Bristol-Myers Squibb by 217.7% during the second quarter. Edge Wealth Management LLC now owns 10,007 shares of the biopharmaceutical company’s stock worth $452,000 after acquiring an additional 6,857 shares in the last quarter. Finally, KG&L Capital Management LLC raised its stake in shares of Bristol-Myers Squibb by 38.6% during the second quarter. KG&L Capital Management LLC now owns 17,104 shares of the biopharmaceutical company’s stock worth $775,000 after acquiring an additional 4,761 shares in the last quarter. Institutional investors own 80.25% of the company’s stock.

NYSE:BMY traded up $0.40 during trading hours on Friday, hitting $52.82. The company had a trading volume of 5,966,796 shares, compared to its average volume of 9,915,286. The company has a market capitalization of $84.78 billion, a PE ratio of 13.27, a price-to-earnings-growth ratio of 2.33 and a beta of 0.72. The stock has a 50-day moving average price of $49.86 and a 200 day moving average price of $47.17. Bristol-Myers Squibb Co has a 52 week low of $42.48 and a 52 week high of $57.53. The company has a debt-to-equity ratio of 1.51, a current ratio of 3.88 and a quick ratio of 3.75.

Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, July 25th. The biopharmaceutical company reported $1.18 EPS for the quarter, beating the Zacks’ consensus estimate of $1.06 by $0.12. Bristol-Myers Squibb had a net margin of 26.14% and a return on equity of 47.63%. The firm had revenue of $6.27 billion for the quarter, compared to analysts’ expectations of $6.10 billion. During the same quarter in the previous year, the business posted $1.01 EPS. The company’s quarterly revenue was up 10.0% on a year-over-year basis. Analysts anticipate that Bristol-Myers Squibb Co will post 4.29 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, November 1st. Stockholders of record on Friday, October 4th will be issued a dividend of $0.41 per share. This represents a $1.64 dividend on an annualized basis and a dividend yield of 3.10%. The ex-dividend date of this dividend is Thursday, October 3rd. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 41.21%.

BMY has been the topic of several research reports. Bank of America initiated coverage on shares of Bristol-Myers Squibb in a research note on Wednesday. They set a “buy” rating and a $60.00 price target on the stock. JPMorgan Chase & Co. set a $62.00 target price on shares of Bristol-Myers Squibb and gave the stock a “buy” rating in a report on Friday, September 13th. Atlantic Securities upgraded shares of Bristol-Myers Squibb from a “neutral” rating to an “overweight” rating and set a $63.00 target price on the stock in a report on Wednesday, August 14th. ValuEngine upgraded shares of Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a report on Monday, October 7th. Finally, TheStreet upgraded shares of Bristol-Myers Squibb from a “c+” rating to a “b-” rating in a report on Wednesday, September 18th. Seven research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. Bristol-Myers Squibb has an average rating of “Buy” and a consensus target price of $56.53.

In other Bristol-Myers Squibb news, Director Robert J. Bertolini bought 11,000 shares of the company’s stock in a transaction dated Wednesday, July 31st. The shares were purchased at an average price of $44.72 per share, for a total transaction of $491,920.00. Following the acquisition, the director now owns 11,397 shares in the company, valued at approximately $509,673.84. The purchase was disclosed in a filing with the SEC, which is available at this link. Insiders own 0.13% of the company’s stock.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Further Reading: Equity Income

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.